Abstract:Changes in protein metabolism are key to disease onset and progression in many neurodegenerative diseases. As a prime example, in Parkinson’s disease, folding, post-translational modification and recycling of the synaptic protein α-synuclein are clearly altered, leading to a progressive accumulation of pathogenic protein species and the formation of intracellular inclusion bodies. Altered protein folding is one of the first steps of an increasingly understood cascade in which α-synuclein forms complex oligomers and finally distinct protein aggregates, termed Lewy bodies and Lewy neurites. In neurons, an elaborated network of chaperone and co-chaperone proteins is instrumental in mediating protein folding and re-folding. In addition to their direct influence on client proteins, chaperones interact with protein degradation pathways such as the ubiquitin-proteasome-system or autophagy in order to ensure the effective removal of irreversibly misfolded and potentially pathogenic proteins. Because of the vital role of proper protein folding for protein homeostasis, a growing number of studies have evaluated the contribution of chaperone proteins to neurodegeneration. We herein review our current understanding of the involvement of chaperones, co-chaperones and chaperone-mediated autophagy in synucleinopathies with a focus on the Hsp90 and Hsp70 chaperone system. We discuss genetic and pathological studies in Parkinson’s disease as well as experimental studies in models of synucleinopathies that explore molecular chaperones and protein degradation pathways as a novel therapeutic target. To this end, we examine the capacity of chaperones to prevent or modulate neurodegeneration and summarize the current progress in models of Parkinson’s disease and related neurodegenerative disorders.

Molecular chaperones and Parkinson's disease

Molecular Chaperones and Co-Chaperones in Parkinson Disease

Molecular Chaperones, Alpha-Synuclein, and Neurodegeneration

Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies

Exploring Heat Shock Proteins As Therapeutic Targets for Parkinson’s Disease

Exploring the complex interplay between Parkinson's disease and BAG proteins

Linking Heat Shock Protein 70 and Parkin in Parkinson’s Disease

Linking Heat Shock Protein 70 and Parkin in Parkinson's Disease.

Chaperone-Mediated Autophagy and Mitochondrial Homeostasis in Parkinson’s Disease

Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson’s disease

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets

Small Molecules, α-Synuclein Pathology, and the Search for Effective Treatments in Parkinson's Disease

DnaJ/Hsp40 Family and Parkinson's Disease

Heat Shock Protein 90 in Parkinson's Disease: Profile of a Serial Killer

Progress relating to mitochondria dysfunction and Parkinson disease

Post-translational Modification and Mitochondrial Function in Parkinson’s Disease

Post-translational modification and mitochondrial function in Parkinson's disease

Parkin, PINK1, DJ-1 and Mitochondria Dysfunctionwith Parkinson’s Disease

Mitochondrial homeostasis regulation: A promising therapeutic target for Parkinson's disease